Viatris to Present at the BofA Securities 2025 Healthcare Conference
Get Alerts VTRS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3%
Revenue Growth %: +1.3%
Join SI Premium – FREE
A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-present-at-the-bofa-securities-2025-healthcare-conference-302437695.html
SOURCE Viatris Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EaseUS Software Reveals Windows Storage Insights Report 2026 H1 Based on 3.8 Million Global Samples
- TICKETS ON SALE NOW FOR "JIM HENSON'S HARMONIOUS HOOPLA," A TRIBUTE TO MUSIC FROM THE WORLDS OF JIM HENSON
- The Modern Shrine Turns Ancient Pattern Systems Into AI Decision Tools After Testing the Method Live
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share